Filing Flows › Organogenesis Holdings (ORGO) › Q3 2025
Organogenesis Holdings (ORGO) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 6, 2025
Organogenesis Holdings (ORGO) reported revenue of $151M for the third quarter 2025 (Q3 2025), +31% from a year earlier and +49% from the quarter before. Operating margin was 13.7%, net earnings $21.6M (14.3% of revenue).
Organogenesis Holdings, Q3 2025: revenue $151M (+31% year over year), operating margin 13.7%, net earnings $21.6M, operating cash flow $3.1M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $151M | +49% | +31% |
| Operating profit | $20.7M | — | +232% |
| Net earnings | $21.6M | — | +75% |
| Operating cash flow | $3.1M | — | -65% |
| Free cash flow | $844K | — | -86% |
What changed
Revenue was $150.9M in Q3 2025, up 31% year over year and up 49% from the previous quarter. Product was the largest line at 100% of revenue. Product added $35.3M year over year (up 31%), 99% of the total change.
Operating profit was $20.7M, a 13.7% margin (up 8.3 points year over year). Of the extra revenue versus a year earlier, 41% reached operating profit, above the 5% margin then. The fastest-growing cost line was Research & development (+28%). Net earnings were $21.6M, up 75% year over year. The effective tax rate was -1.9%.
Operating cash flow was $3.1M (down 65% year over year), 14% of net earnings. Non-cash charges added back $4.9M of depreciation and amortization and $3.1M of share-based compensation. Working capital and other items used $26.4M. Capital expenditures of $2.2M left free cash flow of $844K.
Questions
What was Organogenesis Holdings' revenue in the third quarter 2025?
Organogenesis Holdings (ORGO) reported revenue of $151M for the third quarter 2025 (Q3 2025), +31% from a year earlier and +49% from the quarter before.
Was Organogenesis Holdings profitable in the third quarter 2025?
Operating profit was $20.7M (13.7% of revenue) and net earnings $21.6M.